Loading...
Loading...
Response Genetics, Inc.
RGDX, a company focused on the development and sale of molecular
diagnostic tests that help determine a patient's response to cancer therapy,
today announced that it has executed an agreement with Fortified Provider
Network, Inc. and will join its network of preferred providers. This latest
agreement marks Response's seventh health care payor agreement this year and
brings its access to over 97 million people nationally.
With the execution of this agreement, approximately 4.1 million members
associated with over 200 health insurers, self-funded employers and other
payors of health care services will be able to access Response Genetics' suite
of molecular predictive testing at a discounted rate. Response Genetics'
predictive genomic testing is targeted to patients battling lung, colon,
gastric, and melanoma cancers. The results from Response Genetics' testing
services give treating physicians actionable information that enable the best
therapy to be employed on that specific patient's tumor. The precise nature of
Response Genetics' services brings with them a value proposition that is
expected to improve patient outcomes and enhance efficiencies in health care
delivery.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in